In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From DiaSorin SpA

Deal Watch: Sanofi To Tap Owkin’s AI, Machine Learning In Oncology

French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.

Deal Watch Business Strategies

MeMed’s Mission: Pressing Its Fingerprint Against AMR

Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.

Business Strategies Companies

Deal Watch: Lilly Teams Up With Lycia In Protein Degradation

Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.

Deal Watch Deals

DiaSorin Completes $1.8bn Acquisition Of Luminex

The brokered deal will broaden DiaSorin’s offerings in the rapidly growing liquid diagnostics market, while also providing Luminex furthered access to markets outside of the US.

In Vitro Diagnostics M & A
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Other Names / Subsidiaries
    • Biotrin International
    • DiaSorin Molecuular
    • Focus Diagnostics
UsernamePublicRestriction

Register